The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
{\displaystyle n_{\mathrm {A} }=n_{\mathrm {B} }{\frac {R_{\mathrm {B} }-R_{\mathrm {AB} }}{R_{\mathrm {AB} }-R_{\mathrm {A} }}}\times {\frac {x(^{j}\mathrm {A} )_{\mathrm {B} }}{x(^{j}\mathrm {A} )_{\mathrm {A} }}}}
Carvedilol is both a non-selective β-adrenergic receptor antagonist (β1, β2) and an α-adrenergic receptor antagonist (α1). The S(–) enantiomer accounts for the beta-blocking activity whereas the S(–) and R(+) enantiomers have alpha-blocking activity. The affinity (Ki) of carvedilol for the β-adrenergic receptors is 0.32 nM for the human β1-adrenergic receptor and 0.13 to 0.40 nM for the β2-adrenergic receptor. Using rat proteins, carvedilol has shown affinity for a variety of targets including the β1-adrenergic receptor, β2-adrenergic receptor, α1-adrenergic receptor, α2-adrenergic receptor, 5-HT1A receptor, 5-HT2 receptor, H1 receptor, D2 receptor, μ-opioid receptor, veratridine site of voltage-gated sodium channels, serotonin transporter, norepinephrine transporter, and dopamine transporter. It is an antagonist of the human 5-HT2A receptors with moderate affinity, although it is unclear if this is significant for its pharmacological actions given its much stronger activity at adrenergic receptors. Carvedilol reversibly binds to β-adrenergic receptors on cardiac myocytes. Inhibition of these receptors prevents a response to the sympathetic nervous system, leading to decreased heart rate and contractility. This action is beneficial in heart failure patients where the sympathetic nervous system is activated as a compensatory mechanism. Carvedilol blockade of α1-adrenergic receptors causes vasodilation of blood vessels. This inhibition leads to decreased peripheral vascular resistance and an antihypertensive effect.
=== Dietary === In the United States, many people's diets are excessively high in calories, often due to fast food and sugary beverages. Individuals with obesity may consume more calories before feeling full, experience hunger more quickly, or eat in response to stress or anxiety. Per the USDA's Dietary Guidelines for Americans, 2020-2025, most Americans do not follow a healthy dietary pattern. Few individuals being tested for nutrient levels would be able to meet them without the use of fortification or enrichment. Americans eat an abundance of fast food. 36.6% of adults consume fast food on a given day and 2 out of 3 people consume fast food at least once a week. While the negative effects of fast food, such as lack of nutritional value and high amounts of calories, are widely known, fast food remains popular for its convenience, specifically because it is time-efficient and cheap. Quantity of food consumption plays an important role as well. A study shows a significant increase in food portion sizes of marketplace products since the 1970s that exceed the federal standards for dietary guidance. Reasons for this increase include the expansion of the food industry since the seventies, marketing strategies, and customer demand. Extreme differences in portion sizes between the same menu items of the same franchises have also been observed. In some instances, American food portion sizes are as much as double the size of their British counterparts.
There are two major classifications of 2D liquid chromatography. These include: Comprehensive 2D liquid chromatography (LCxLC) and Heart-cutting 2D liquid chromatography (LC-LC). In comprehensive 2D-LC, all the peaks from a column elution are fully sampled, but it has been deemed unnecessary to transfer the entire sample from the first to the second column. A portion of the sample is sent to waste while the rest is sent to the sampling valve. In heart-cutting 2D-LC specific peaks are targeted with only a small portion of the peak being injected onto a second column. Heart-cutting 2D-LC has proven to be quite useful for sample analysis of substances that are not very complex provided they have similar retention behavior. Compared to comprehensive 2D-LC, heart-cutting 2D-LC provides an effective technique with much less system setup and a much lower operating cost. Multiple heart-cutting (mLC-LC) may be utilized to sample multiple peaks from first dimensional analysis without risking temporary overlap of second dimensional analysis. Multiple heart-cutting (mLC-LC) utilizes a setup of multiple sampling loops. For 2D-LC, peak capacity is a very important issue. This can be generated using gradient elution separation with much greater efficiency than an isocratic separation given a reasonable amount of time. While isocratic elution is much easier on a fast time scale, it is preferable to perform a gradient elution separation in the second dimension. The mobile phase strength is varied from a weak eluent composition to a stronger one.
Sources: en.wikipedia.org
== Biography == Langevin received an MD degree from McGill University in 1978. She did a post doctoral research fellowship in Neurochemistry at the MRC Neurochemical Pharmacology Unit in Cambridge, England, a residency in Internal Medicine and a fellowship in Endocrinology and Metabolism at Johns Hopkins Hospital. She was a Professor in Residence of Medicine at Harvard Medical School, Brigham and Women's Hospital. She was also a part-time Professor of Neurology, Orthopedics and Rehabilitation at the University of Vermont College of Medicine. She was the Principal Investigator of two NIH-funded studies investigating the role of connective tissue in low back pain and the mechanisms of manual and movement based therapies. Her previous studies in humans and animal models have found that "needle grasp", the biomechanical component of de qi, may be caused by connective tissue winding around the needle. Helene Langevin was appointed as Director of the Osher Center for Integrative Medicine at Harvard Medical School and Brigham and Women's Hospital in November 2012.
=== La–Lem === Marc Lacroix (b. 1963). Belgian biochemist at the Institut Jules Bordet (Brussels), who specializes in breast cancer biology, metastasis and therapy. Keith Laidler (1916–2003). British-Canadian chemist and biochemist at the University of Ottawa. Expert on chemical and enzyme kinetics. Fellow of the Royal Society of Canada. Henry Lardy (1917–2010). American biochemist at the University of Wisconsin, noted for work on metabolism. Member Natl. Acad. Sci. USA. Michel Lazdunski (b. 1938). French biochemist and neuroscientist at Sophia Antipolis. Known especially for work on ion channels. Full Member of the French Academy of Sciences. Jack Legge (1917–1996). Australian biochemist known for his work on blood pigment metabolism and participation in mustard gas trials on Australian Defence Force volunteers during WW2. Albert L. Lehninger (1917–1986). American biochemist at the University of Wisconsin. He discovered, with Eugene P. Kennedy, that mitochondria are the site of oxidative phosphorylation in eukaryotes. Author of several influential texts, including The Mitochondrion, Bioenergetics and Biochemistry. Member Natl. Acad. Sci. USA. Luis Federico Leloir FRS (foreign associate) (1906–1987). Argentinian biochemist at the Fundación Instituto Campomar (Buenos Aires) who worked on sugar nucleotides, carbohydrate metabolism, and renal hypertension. Nobel Prize for Chemistry (1970). Rudi Lemberg FRS (1896–1975). German-Australian biochemist, director of the Kolling Institute of Medical Research from 1935 to 1972. Known for porphyrin research.
This inhibition can lead to a depletion of dopamine and norepinepherine in the brain due to the lack of the precursor L-DOPA (L-3,4-dyhydroxyphenylalanine) which is synthesized by tyrosine hydroxylase. This drug is rarely used and can cause depression, but it is useful in treating pheochromocytoma and also resistant hypertension. Older examples of inhibitors mentioned in the literature include oudenone and aquayamycin.
There is a dose-dependent increase in the QT interval and the corrected QT interval (QTc). Because of this, many practitioners will initiate dofetilide therapy only on individuals under telemetry monitoring or if serial EKG measurements of QT and QTc can be performed.
Artificial white blood cells are typically membrane bound vesicles designed to mimic the immunomodulatory behavior of naturally produced leukocytes. While extensive research has been done with regards to artificial red blood cells and platelets for use in emergency blood transfusions, research into artificial white blood cells has been focused on increasing the immunogenic response within a host to treat cancer or deliver drugs in a more favorable fashion. While certain limitations have prevented leukocyte mimicking particles from becoming widely used and approved by regulatory bodies (e.g., US FDA, EU EMA, UK MHRA, JP PMDA, AU TGA), more research is being allocated to this area of synthetic blood which has the potential for producing a new form of treatment for cancer and other diseases.
Sources: en.wikipedia.org
=== Chemical === Bohrium is the fifth member of the 6d series of transition metals and the heaviest member of group 7 in the periodic table, below manganese, technetium and rhenium. All the members of the group readily portray their group oxidation state of +7 and the state becomes more stable as the group is descended. Thus bohrium is expected to form a stable +7 state. Technetium also shows a stable +4 state whilst rhenium exhibits stable +4 and +3 states. Bohrium may therefore show these lower states as well. The higher +7 oxidation state is more likely to exist in oxyanions, such as perbohrate, BhO−4, analogous to the lighter permanganate, pertechnetate, and perrhenate. Nevertheless, bohrium(VII) is likely to be unstable in aqueous solution, and would probably be easily reduced to the more stable bohrium(IV). The lighter group 7 elements are known to form volatile heptoxides M2O7 (M = Mn, Tc, Re), so bohrium should also form the volatile oxide Bh2O7. The oxide should dissolve in water to form perbohric acid, HBhO4. Rhenium and technetium form a range of oxyhalides from the halogenation of the oxide. The chlorination of the oxide forms the oxychlorides MO3Cl, so BhO3Cl should be formed in this reaction. Fluorination results in MO3F and MO2F3 for the heavier elements in addition to the rhenium compounds ReOF5 and ReF7. Therefore, oxyfluoride formation for bohrium may help to indicate eka-rhenium properties.
In mid September, the US House of Representatives voted for a third time, to end the war, shortly after a CBO report warned the conflict had already cost at least $38 billion, was depleting defensive missile stockpiles to the point of a five-year rebuild, and would add roughly $3 billion per month while fueling inflation.
The same day, Hitler met with Chamberlain and demanded the swift takeover of the Sudetenland by Nazi Germany under threat of war. Czechoslovakia, Hitler claimed, was slaughtering the Sudeten Germans. Chamberlain referred the demand to the British and French governments, both of which accepted. The Czechoslovak government resisted by arguing that Hitler's proposal would ruin the nation's economy and ultimately lead to German control of all of Czechoslovakia. The United Kingdom and France issued an ultimatum and made a French commitment to Czechoslovakia contingent upon its acceptance. On 21 September, Czechoslovakia capitulated. The next day, however, Hitler added new demands that insisted for the claims of Poland and Hungary to be satisfied as well. Romania was also invited to share in the division of Carpathian Ruthenia but refused because it was an ally of Czechoslovakia (see Little Entente). The Czechoslovak capitulation precipitated an outburst of national indignation. In demonstrations and rallies, Czechs and Slovaks called for a strong military government to defend the integrity of the state. A new cabinet, under General Jan Syrový, was installed, and on 23 September 1938, a decree of general mobilization was issued. The Czechoslovak Army was modern, had an excellent system of frontier fortifications and was prepared to fight. The Soviet Union announced its willingness to come to Czechoslovakia's assistance. Beneš, however, refused to go to war without the support of the Western powers.
Over-expression of human wild-type or A53T-mutant alpha-synuclein in primates drives deposition of alpha-synuclein in the ventral midbrain, degeneration of the dopaminergic system and impaired motor performance. Although the accumulation and aggregation of alpha-synuclein in most Parkinson's disease patients primarily result from posttranscriptional mechanisms, targeting its production remains a potential therapeutic approach. Research indicates that microRNA-7 and the naturally occurring small molecule quercetin can reduce alpha-synuclein levels under experimental conditions. Certain sections of the alpha-synuclein protein may play a role in the tauopathies. In children with autism spectrum disorders, the serum levels of alpha-synuclein have been reported to be significantly higher. A correlation to higher levels of e.coli and pro-inflammatory gut microbiome in those patients and an approach through disease modifying polysaccharides has been reported in clinical pilot studies. A prion form of the protein alpha-synuclein may be a causal agent for the disease multiple system atrophy.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.